A Phase 1 interventional study of AD-120A and AD-120 in Gastroesophageal Reflux Disease (GERD), sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 21 in phase 1, and was the 61st registered.
1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.
Browse Gastroesophageal Reflux studies →8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
Incheon St.Mary's Hospital · Sites in Korea, Republic of
Ages 19+
Jeil Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19–75
HK inno.N Corporation · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 6 · Phase 3 11 · Phase 4 8
First in 2006; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 68 across 800 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 54 across the 52 interventional studies, 2,000 across the 19 observational. Of the 51 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
Yuhan Corporation has 5 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastroesophageal Reflux with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07678177HK inno.N CorporationAn Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-120 compared with AD-120A in healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 : Test Drug (AD-120), Period 2 : Reference Drug (AD-120A)
Drug: AD-120A · Drug: AD-120
Period 1 : Reference Drug (AD-120A), Period 2 : Test Drug (AD-120)
Drug: AD-120A · Drug: AD-120
Administered before the breakfast during 7 days, Oral, Tablet
Also known as: Reference Drug
Administered before the breakfast during 7 days, Oral, Tablet
Also known as: Test drug
Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ,ss)
AUCτ,ss after 7days repeated administration of Omeprazole
Time frame: AUCτ,ss: pre-dose to 24 hours of 1st administration versus pre-dose to 24 hours of repeated administration (7days)
The time of peak concentration after single dose
Tmax after 1days administration of Omeprazole
Time frame: Tmax: from pre-dose to 24 hours of 1st administration
Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring
Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoring for 24-hour interval after 7th dose
Time frame: 24 hours before 1st administration to 24 hours after repeated administration (7days)
Start is estimated for Apr 2025; primary completion for Sep 2025, 4 months later.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 4 months is close to that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.